Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody (Q39093873)

9 September 2017

Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody (English)

1 reference

9 September 2017

Kobra Omidfar

1

1 reference

9 September 2017

Fatemeh Sadat Amjad Zanjani

2

1 reference

9 September 2017

Arghavan Golbaz Hagh

3

1 reference

9 September 2017

Maedeh Darziani Azizi

4

1 reference

9 September 2017

Seyed Javad Rasouli

5

1 reference

9 September 2017

Susan Kashanian

6

1 reference

9 September 2017

20 September 2013

1 reference

Molecular Biology Reports

9 September 2017

1 reference

9 September 2017

40

1 reference

9 September 2017

12

1 reference

9 September 2017

6737-6745

1 reference

https://scigraph.springernature.com/pub.10.1007/s11033-013-2790-1

9 September 2017

0 references

cites work

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Single domain antibodies: a new concept for epidermal growth factor receptor and EGFRvIII targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Single-domain antibody fragments with high conformational stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Naturally occurring antibodies devoid of light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Single domain camel antibodies: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Studies of thermostability in Camelus bactrianus (Bactrian camel) single-domain antibody specific for the mutant epidermal-growth-factor receptor expressed by Pichia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Production of a novel camel single-domain antibody specific for the type III mutant EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

The state of antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

New analytical applications of gold nanoparticles as label in antibody based sensors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

Downregulation of EGFR by a novel multivalent nanobody-liposome platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-013-2790-1

["Camel nanoantibody" is an efficient tool for research, diagnostics and therapy]

21 January 2018

1 reference

12 December 2020

Increased levels of recombinant human proteins with the Escherichia coli strain Rosetta(DE3)

1 reference

12 December 2020

Nanobodies - from llamas to therapeutic proteins

1 reference

12 December 2020

Camel heavy chain antibodies against prostate-specific membrane antigen.

1 reference

12 December 2020

Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer

1 reference

12 December 2020

10.1007/S11033-013-2790-1

Identifiers

DOI

1 reference

9 September 2017

1 reference